Ga-labeled prostate-specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography imaging (PET/CT) is a rapidly evolving imaging modality for prostate cancer. Many studies have proved its superiority in staging, restaging, and detecting the recurrent prostate cancer. However, case reports describing the incidental tracer uptake in benign and nonprostatic malignancies are also reported in the literature, thus questioning the specificity of the tracer. This pictorial assay illustrates the nonspecific tracer uptake encountered during PSMA PET/CT imaging, knowledge of which can increase the confidence of interpreting physicians and may also open a new path for peptide receptor radionuclide therapy in nonprostatic malignancies. How to cite this article: Malik D, Sood A, Mittal BR, Singh H, Basher RK, Shukla J, et al. Nonspecific uptake of 68 Ga-prostate-specific membrane antigen in diseases other than prostate malignancy on positron emission tomography/computed tomography imaging: A pictorial assay and review of literature. Indian J Nucl Med 2018;33:317-25.
Introduction
Prostate-specific membrane antigen (PSMA) a type II transmembrane glycoprotein is overexpressed in prostate cancer which further increases manifold with tumor grade and stage. [1] The level of PSMA expression increases with tumor dedifferentiation, metastatic disease, and hormone resistance. [2] PSMA was initially detected in the prostate gland, hence the name. However, eventual histopathological studies have shown its expression in salivary glands, duodenal epithelium, lacrimal glands, proximal tubule cells in the kidney, and tumor-associated vascular endothelium. [3, 4] It is known that PSMA participates in matrix degradation and facilitates integrin signaling and p21-activated kinase activation causing tumor invasion. Role of PSMA in regulating angiogenesis has been postulated; however, its exact mechanism is unknown. [5] The development of PSMA-targeted small molecule labeled with 68 Ga has allowed the molecular imaging of prostate cancer by positron emission tomography (PET). 68 Ga-labeled PSMA (also known as 68 Ga-PSMA-HBED-CC) since its introduction in the year 2011 has revolutionized the imaging and management of prostate cancer. [6] It is now being increasingly used for whole-body primary staging of intermediate-or high-risk prostate cancer or restaging after biochemical evidence of recurrence (rising prostate-specific antigen levels) in patients with prior radical prostatectomy and/or after radical external beam radiation. [7, 8] Perera et al. in a meta-analysis showed that 68 Ga-labeled PSMA PET/ computed tomography (CT) in advanced prostate cancer had a sensitivity of 80% and specificity of 97% on per lesion analysis. [9] For overall bone involvement in patients with prostate cancer, the sensitivity and specificity have been found to be 99%-100% and 88%-100%, respectively. [10] However, with increasing experience of imaging with PSMA-labeled radiotracers, expression of PSMA has been demonstrated in various nonprostatic malignant and nonmalignant conditions leading to potential pitfalls in the interpretation of PSMA-targeted imaging.
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com
Nevertheless, this drawback may prove beneficial in imaging and therapeutic target for other nonprostatic conditions. Here, we present a few cases showing PSMA expression in unexpected sites encountered during 68 Ga-labeled PSMA PET/CT imaging.
Benign Diseases
Meningioma 68 Ga-labeled PSMA normally does not show tracer uptake in the normal brain parenchyma providing high precision for the detection of brain metastasis from prostate cancer. [6] Focal 68 Ga-PSMA avidity has been reported in few isolated case reports in meningiomas in the past. This tracer uptake may be either due to the PSMA expression in the tumor vasculature or due to the blood pool effect. [11] Although brain metastases from prostate cancer is a rare occurrence, 68 Ga-PSMA uptake in the brain should be interpreted with caution and should be correlated with CT/magnetic resonance imaging findings [ Figure 1 ].
Cerebral infarct/hemorrhage
68 Ga-labeled PSMA PET/CT provides excellent diagnostic value in the detection of brain metastasis and primary brain tumors, as normal brain parenchyma essentially shows no PSMA tracer uptake in the presence of an intact blood-brain barrier. [12] However, breach in blood-brain barrier may lead to nonspecific tracer accumulation in infarct/hemorrhage site due to increased permeability of tracer as well as the simultaneous occurrence of reparative processes (characterized by neovascularization) at these sites. [13] Hence, visualization of tracer avidity in subacute cerebral infarction on PSMA PET/CT may potentially mimic the brain metastasis [ Figure 2 ]. 68 Ga-PSMA uptake in lung parenchyma has been documented in metastases from prostate cancer and nonprostate malignancies, primary lung cancer, and benign etiologies such as tuberculosis, sarcoidosis, anthracosilicosis, benign lung opacities, and bronchiectasis. [14] [15] [16] [17] [18] Although tracer uptake in the nonprostatic malignancies has been attributed to PSMA expression in the tumor neovasculature endothelial cells, uptake in the benign pathologies is likely due to increased capillary permeability caused by infection or inflammation leading to tracer accumulation in the interstitial space. Thus, cautious interpretation of the scan is required, especially in India where infective pathologies such as tuberculosis are endemic which may lead to over staging of the disease [ Figure 3 ].
Lung consolidation

Gynecomastia
Androgen deprivation therapy is therapeutic treatment for asymptomatic high risk, locally advanced prostate cancer given in isolation or combined with external beam radiotherapy. Androgen deprivation either by medical or surgical castration is known to cause gynecomastia with an incidence as high as 75%. Gynecomastia is the result of an imbalance between estrogens and androgens in breast tissue with a high level of estrogen causing the growth of the breast tissue. [19, 20] Although localization of 68 Ga-labeled PSMA in the breast parenchyma has been well documented in the neovasculature of breast cancer, it is essential to know that PSMA expression is also seen in gynecomastia [ Figure 4 ]. [21, 22] 
Inferior vena cava thrombus
Prostate cancer is associated with increased risk of thromboembolic disease. The risk of thromboembolic disease increases exponentially with age, and the patient on hormonal therapy has the highest risk of the thromboembolic event. [23] PSMA uptake in thrombi are likely caused by nonspecific tracer binding and are in the part of noise related [ Figure 5 ]. [24] The rapidly expanding role of 68 Ga-labeled PSMA PET/CT in prostate cancer needs careful evaluation as its specificity is limited by some false-positive findings as enumerated in the present article [ Table 1 ]. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] Knowledge of these 
Malignant Diseases
With the rapid evolution of PET from a pure research tool to an imaging modality with enormous clinical potential, especially in oncology, 18 F-fluorodeoxyglucose (FDG) an analog of glucose metabolism has been increasingly used for the staging and restaging of most of the solid tumors.
Although most of the solid tumors are FDG avidity, some tumors such as prostate cancer, well-differentiated neuroendocrine tumor, renal cell carcinoma (RCC), hepatocellular carcinoma, and low-grade lymphoma shows low FDG avidity. [44] More clinical research led to the development of various other non-FDG avid tracers. 68 Ga easily available from Ge-68/Ga-68 generator was labeled with various peptides and used for imaging of neuroendocrine tumors and prostate cancer, etc. 68 Ga-labeled PSMA PET/CT is now considered as the reference standard for prostate cancer imaging. [9, 10] As the experience with 68 Ga-labeled PSMA PET/CT for prostate imaging is increasing its nonspecific uptake at the other malignancies apart from prostate cancer are being reported. Several isolated case reports have shown incidental PSMA avidity in high-grade gliomas, lung cancer, breast cancer, multiple myeloma, and malignant melanoma, etc. [ Table 2 ]. [21, The 68 Ga-labeled PSMA avidity in these various nonprostatic malignancies has been ascribed to the PSMA expression in the endothelial cells of the tumor neovasculature.
Focal PSMA accumulation at unexpected places needs careful evaluation, as observed in the present series, incidental focal PSMA avidity in the rectum [ Figure 6 ], and Figure 7 ]. Histopathological examination of these lesions revealed adenocarcinoma of the rectum and papillary thyroid cancer, respectively. The authors have already reported few other malignancies such as radioactive iodine-refractory thyroid cancer, gastroesophageal carcinoma, signet ring cell, and urinary bladder carcinoma showing PSMA avidity. [51, 53] Among nonprostate cancers studied by 68 Ga-labeled PSMA PET/CT, RCC is by far the most abundant entity. Of the published isolated case reports, 68 Ga-labeled PSMA PET/CT is found to be superior in terms of lesion detection in comparison to FDG PET/CT and conventional imaging. [67] Moreover, PSMA provides a definite advantage over FDG in the detection of brain metastasis due to the absence of tracer uptake in normal brain parenchyma [ Figure 8 ]. The finding of PSMA expression in these malignancies provides interesting diagnostic and radioligand-based therapeutic options.
Conclusion
68
Ga-labeled PSMA PET/CT is generally considered to be highly sensitive and specific for the prostate cancer, but PSMA, as publicized earlier, is not an exclusive marker of prostate cancer. A growing number of reports and present pictorial assay indicate the possibility of false-positive PSMA accumulation in various nonprostatic benign and malignant pathologies. Knowledge of the false-positive tracer uptake of 68 Ga-labeled PSMA helps in improving the reporting of 68 Ga-PSMA for prostate cancer imaging. Despite the reports on false-positive tracer uptake in nonprostate conditions, 68 Ga-labeled PSMA is the most accurate tracer available for imaging prostate cancer. This nonexclusivity of PSMA avidity opens a window to utilize the variety of accessible radioactive PSMA ligands for imaging and possibility of nuclear theranostic in a few other nonprostate malignancies. [25] Brain Meningioma Noto et al. [26] Cerebral infarction Vadi et al. [27] Neurocysticercosis Kanthan et al. [28] Thyroid Follicular adenoma Elri et al. [29] Lung Anthracosis Bouchelouche and Vendelbo [17] Benign lung opacities and bronchiectasis Pyka et al. [30] Reactivated tuberculosis Malik et al. [31] Breast Pseudo-angiomatous stromal hyperplasia of breast Sasikumar et al. [22] Gynaecomastia Bhardwaj et al. [32] Liver Haemangioma Hermann et al. [33] Sarcoidosis Chan et al. [34] Pancreas Pancreatic serous cystadenoma Kobe et al. [35] Spleen Sarcoidosis Law et al. [36] Adrenal Lipid rich adrenal adenoma Froehner et al. [37] Bone Paget's disease De Coster et al. [38] Benign fibrous dysplasia Vamadevan et al. [39] Vertebral body fracture Kanthan et al. [40] Miscellaneous Desmoid tumor Zacho et al. [41] Intramuscular myxoma Malik et al. [42] Liposarcoma: Well-differentiated Vamadevan et al. [43] Peripheral nerve sheath tumor 
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